Key highlights
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 215 Press Releases
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
PARIS, FRANCE, 1 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Christelle Huguet as Executive Vice President, Head of Research and Development. She will succeed Howard Mayer, EVP and Head…
IPSEN – Buy-back programme – Art 5 of MAR – Week 34 – 2023
Aggregated presentation by day and by market
IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2023
Aggregated presentation by day and by market

21 August 2023
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in…